Related Experiment Video
Updated: Jun 12, 2025
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
461
Structure-based virtual screening discovers novel PKMYT1 inhibitors.
Haoyu Zhang1,2,3, Jinyu Yu1,2,3, Ziheng Yang1,2,3
1Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University Shenyang 110016 China medchemzhao@163.com.
RSC Medicinal Chemistry
|September 23, 2024
Summary
Natural compounds EGCG, GCG, and luteolin show potent inhibition of PKMYT1 kinase, a promising cancer therapy target. Molecular simulations reveal key binding interactions, guiding future drug development for PKMYT1 inhibitors.
Area of Science:
- Molecular Biology
- Biochemistry
- Pharmacology
Background:
- PKMYT1 (a WEE family member) is critical for cell cycle regulation by phosphorylating CDK1-CyclinB.
- PKMYT1 kinase is a promising therapeutic target in oncology, especially given synthetic lethality observed with CCNE1 amplification.
- Current PKMYT1 inhibitors are limited, necessitating the discovery of novel compounds.
Purpose of the Study:
- To identify novel natural product inhibitors of PKMYT1 kinase.
- To characterize the inhibitory activity and binding mechanisms of identified compounds.
Main Methods:
- Virtual screening of a natural product library.
- In vitro enzyme inhibition assays to determine IC50 values.
- Molecular simulation techniques to analyze compound-protein interactions.
Main Results:
- EGCG, GCG, and luteolin demonstrated potent PKMYT1 inhibition with IC50 values of 0.137 μM, 0.159 μM, and 1.5 μM, respectively.
- Molecular simulations identified crucial hydrogen bonds with Asp251 and Glu157 in the DFG region as vital for binding.
- Binding interactions in the DFG region were found to be more significant than those in the hinge and loop regions.
Conclusions:
- EGCG, GCG, and luteolin are effective PKMYT1 inhibitors with potential for cancer therapy.
- Understanding the binding interactions, particularly in the DFG region, is key for designing next-generation PKMYT1 inhibitors.
- These findings offer a new avenue for developing targeted cancer treatments by inhibiting PKMYT1.
